Erratum to Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer

Yuxiang Wang, Xian Li, Xueling Liu, Yi Chen, Chunhao Yang, Cun Tan, Bobo Wang, Yiming Sun,Xi Zhang, Yinglei Gao, Jian Ding, Linghua Meng

1Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; 2University of Chinese Academy of Sciences, Beijing 100049, China; 3Division of Anti-Tumor Pharmacology,State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; 4Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences,Shanghai 200120, China

In the published Figure 11, errors appeared in Figure 1B on page 69. In Figure 1B, bands for p-Akt S473, Akt, and Actin in H1355 cells were mistakenly placed. Here, we have updated Figure 1B to correct the mistake above. The errors do not impact the conclusions of this article. We apologize for the errors and for any confusion it may have caused.

Figure 1B NSCLC cells were treated with CYH33 at the indicated concentrations for 1 h. Cell lysates were subjected to Western blot with the indicated antibodies.